Which country is durvalumab (durvalumab) produced in and its global listing and originator information?

Durvalumab (Durvalumab) is a humanized anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor, mainly used to treat locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and some urothelial cancers. The drug, developed and produced by AstraZeneca in the United States, is one of the world's first PD-L1 inhibitors. It blocks the binding of PD-L1 on the surface of tumor cells to the PD-1 receptor of T cells, thereby restoring the anti-tumor activity of T cells, thus exerting an immunotherapy effect.

Globally, durvalumab has been launched in China, the United States, Europe, Asia and other countries and regions. The US FDA approved it for maintenance treatment of patients with unresectable stage III NSCLC in 2017. Subsequently, the European EMA and other countries also successively approved it for similar indications and patients with urothelial cancer. Its launch provides an effective immunotherapy option for patients with advanced lung cancer and partial urinary system tumors, and is especially suitable for maintenance treatment after previous chemotherapy and radiotherapy.

Durvalumab's original drug is sold in various specifications around the world. The common dosage is intravenous injection every 2 weeks or every 4 weeks. The dosage is adjusted according to the patient's weight and indications. Its global supply is managed by AstraZeneca, and a comprehensive logistics and distribution network has been established in multiple regions to ensure the continuity of medication for clinical patients. Original drugs are more expensive in the early stages of their launch, but with medical insurance negotiations and the inclusion of clinical guidelines in some regions, patients can obtain certain reimbursement support through relevant channels.
Overall, durvalumab, as a PD-L1 inhibitor developed by AstraZeneca, is relatively mature in its global launch and supply. Its original drug has become the standard immunotherapy option for advanced unresectable lung cancer and urothelial cancer, with clear clinical efficacy and good tolerability. In the future, with the release of more clinical research data and the implementation of medical insurance policies in different countries, the accessibility of durvalumab will be further improved, providing more cancer patients with precise immunotherapy solutions.
Keyword tags: durvalumab, PD-L1 inhibitor, non-small cell lung cancer, manufacturer, global launch
Reference: https://www.fda.gov/drugs/resources-information-approved-drugs/durvalumab-imfinzi